Vaginal delivery of contraceptives

Expert Opinion on Drug Delivery

Volumn 2, Issue 4, 2005, Pages 729-736

  Sitruk Ware, Regine ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

Contraceptive steroid; Contraceptive vaginal ring; Controlled release; Dual protection; Long acting system; Vaginal delivery

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL PLUS ETHINYLESTRADIOL; ELCOMETRINE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; LEVONORGESTREL; SPERMICIDAL AGENT;

BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTRACEPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYDROGEL; MENSTRUAL CYCLE; NAUSEA; OVULATION INHIBITION; PREGNANCY RATE; PRESCRIPTION; REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINA DISCHARGE; VAGINA RING; VOMITING;

CONTRACEPTIVE AGENTS; CONTRACEPTIVE DEVICES, FEMALE; DRUG DESIGN; ESTROGENS; FEMALE; GELS; HUMANS; HYDROGELS; OVULATION; PROGESTERONE; SPERMATOCIDAL AGENTS; VAGINA;

EID: 22844452604     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.4.729     Document Type: Review

References (45)

1. ALEXANDER NJ, BAKER E, KAPTEIN M, KARCK U, MILLER L, ZAMPAGLIONE E: Why consider vaginal drug administration? Fertil. Steril. (2004) 82:1-12.
2. MISHELL DR Jr, TALAS M, PARLOW AF, MOYER DL: Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am. J. Obstet. Gynecol. (1970) 107(1):100-107.
3. LANDGREN BM, JOHANNISSON E, MASIRONI B, DICZFALUSY E: Pharmacokinetic and pharmacodynamic effects of small doses of norethisterone released from vaginal rings continuously during 90 days. Contraception (1979) 19(3):253-271.
4. TOIVONEN J: Intravaginal contraception with the synthetic progestin, R2010. Contraception (1979) 20(5):511-518
5. KOETSAWANG S, JI G, KRISHNA U et al.: Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Contraception (1990) 41(2):105-124.
6. BRACHE V, MISHELL DR, LAHTEENMÄKI P et al.: Ovarian function during use of vaginal rings delivering three different doses of Nestorone®. Contraception (2001) 63:257-261.
7. DIAZ S, MIRANDA P, BRANSEIS A, CARDENAS H, CROXATTO HB: Mechanism of action of progesterone as contraceptive for lactating women. Ann. NY Acad. Sci. (1991) 626:11-21.
8. MASSAI R, DIAZ S, JACKANICZ T, CROXATTO HB: Vaginal rings for contraception in lactating women. Steroids (2000) 65(10-11):703-707.
9. AHREN T, VICTOR A, LITHELL H, VESSBY B, JACKANICZ TM, JOHANSSON ED: Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins. Contraception (1983) 28(4):315-327.
10. VICTOR A, LITHELL H, SELINUS I, VESSBY B: Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns. Ups. J. Med. Sci. (1984) 89(2):179-188.
11. SIVIN I, MISHELL DR Jr, VICTOR A et al.: A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. III-Menstrual patterns. An international comparative trial. Contraception (1981) 24(4):377-392.
12. BALLAGH SA, MISHELL DR Jr, LACARRA M, SHOUPE D, JACKANICZ TM, EGGENA P: Contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol. Contraception (1994) 50:517-533.
13. WEISBERG E, FRASER IS, MISHELL DR Jr et al.: A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception (1999) 59:305-310.
14. APTER D, CACCIATORE B, STENMAN UH, ALAPIESSA U, ASSENDORP R: Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol. Contraception (1990) 42(3):285-295.
15. MULDERS TM, DIEBEN TO, BENNINK HJ: Ovarian function with a novel combined contraceptive vaginal ring. Hum. Reprod. (2002) 17:2594-2599.
16. LAURIKKA-ROUTTI M, HAUKKAHNA M, HEIKINHEIMO O: A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception (1990) 42(1):111-120.
17. JACKANICZ TM: Vaginal rings for delivery of Nestorone® progestin for contraception. Eur. J. Contraception Reproduct. Health Care (2000) 5(1):38.
18. SIVIN I, MISHELL DR Jr, ALVAREZ F et al.: Contraceptive vaginal rings releasing Nestorone and ethinyl-estradiol: a 1-year dose-finding trial. Contraception (2005) 71(2):122-129.
19. SIVIN I, DIAZ S, CROXATTO HB et al.: Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception (1997) 55(4):225-232.
20. TITIA M, MULDERS T, DIEBEN TO: Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil. Steril. (2001) 75(5):865-870.
21. COUTINHO EM, COUTINHO EJ, GONCALVES MT, BARBOSA IC: Ovulation suppression in women following vaginal administration of oral contraceptive tablets. Fertil. Steril. (1982) 38(3):380-381.
22. JOHANSSON ED, SITRUK-WARE R: New delivery systems in contraception. Vaginal rings. Am. J. Obstet. Gynecol. (2004) 190(4 Suppl.):S54-S59.
23. SITRUK-WARE R: Delivery Options for Contraceptives. Drug Discov. Today (2005) (In press).
24. DE ZIEGLER D, BULLETTI C, DE MONSTIER B, JAASKELAINEN AS: The first uterine pass effect. Ann. NY Acad. Sci. (1997) 26(828):291-299.
25. CICINELLI E, DE ZIEGLER D, BULLETTI C, MATTEO MG, SCHONAUER LM, GALANTINO P: Direct transport of progesterone from vagina to uterus. Obstet. Gynecol. (2000) 95(3):403-406.
26. WEISBERG E, FRASER IS, MISHELL DR Jr, LACARRA M, BARDIN CW: The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception (1995) 51(1):39-44.
27. SITRUK-WARE R: Pharmacological profile of progestins. Maturitas (2004) 47:277-283.
28. KUMAR N, KOIDE SS, TSONG Y, SUNDARAM K: Nestorone: a progestin with a unique pharmacological profile. Steroids (2000) 65(10-11):629-636.
29. SITRUK-WARE R, SMALL M, KUMAR N, TSONG YY, SUNDARAM K, JACKANICZ T: Nestorone® clinical applications for contraception and HRT. Steroids (2003) 68:907-913.
30. ROUMEN FJ, APTER D, MULDERS TM, DIEBEN TO: Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol. Human Reprod. (2001) 16(3):469-475.
31. SHOUPE D, MISHELL DR Jr: Contraceptive vaginal rings. In: Progestins and Antiprogestins in Clinical Practice. R Sitruk-Ware, D Mishell Jr (Eds), Marcel Dekker, New York, NY, USA (2000):245-257.
32. LAHTEENMÄKKI P, JUKARAINEN H: Novel delivery systems in contraception. Br. Med. Bull. (2000) 56(3):739-748.
33. FU H DARROCH JF, HAAS T, RANJIT N: Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam. Plann. Perspect. (1999) 31:56-63.
34. BALLAGH SA, BABB TB, KOVALEVSKY G, ARCHER DF: Contraceptive ring compliance: as labeled versus calendar based use. 59th Annual Meeting of the American Society for Reproductive Medicine. Fertil. Steril. (2003) 80(S3):S54.
35. TIMMER CJ, MULDERS TM: Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet. (2000) 39(3):233-242.
36. FRASER IS, LACARRA M, MISHELL DR Jr et al.: Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception (2000) 61:131-138.
37. FRASER IS, LAHTEENMÄKKI P, ELOMAA K et al.: Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active women. Hum. Reproduction (1999) 14:1974-1978.
38. VERHOEVEN CH, VAN DEN HEUVEL MW, MULDERS TM, DIEBEN TO: The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception (2004) 69(2):129-132.
39. MAGNUSDOTTIR EM, BJARNADOTTIR RI, ONUNDARSSON PT et al.: The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study. Contraception (2004) 69(6):461-467.
40. GOEBELSMANN U, MASHCHAK CA, MISHELL DR Jr: Comparison of hepatic impact of oral and vaginal administration of ethinyt estradiol. Am. J. Obstet. Gynecol. (1985) 151(7):868-877.
41. RAD M, SITRUK-WARE R, KLUFT C et al.: Comparative effects of a contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol, and a combined oral contraceptive containing levonorgestrel, on lipids and inflammation markers of arterial disease. International Symposium on Thrombosis & Hemostasis (2005) (In press).
42. NOVAK A, DE LA LOGE C, ABETZ L, VAN DER MEULEN EA: The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception (2003) 67:187-194.
43. BALLAGH SA, BAKER JM, HENRY DM, ARCHER DF: Safety of single daily use for one week of C31G HEC gel in women. Contraception (2002) 66(5):369-375.
44. PHILLIPS DM, MAGUIRE RA: The development of microbicides for clinical use to prevent sexually transmitted diseases. Curr Infect Dis Rep. (2002) 4(2):135-140.
45. SAXENA BB, SINGH M, GOSPIN RM, CHU CC, LEDGER WJ: Efficacy of nonhormonal vaginal contraceptives from a hydrogel delivery system. Contraception (2004) 70(3):213-219.